Page 1

● ● O Revenues of $ 3.9 billion GAAP diluted EPS of $ 0.26 Non - GAAP diluted EPS of $ 0.59 Cash flow generated from operating activities of $ 529 million Free cash flow of $ 795 million Full year 2021 business outlook reaffirmed O teva O TEVA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS Net revenues of $ 16.0 - $ 16.4 billion Adjusted EBITDA of $ 4.8 - $ 5.1 billion EPS of $ 2.50 - $ 2.70 Free cash flow of $ 2.0 - $ 2.3 billion Tel Aviv , October 27 , 2021 - Teva Pharmaceutical Industries Ltd. ( NYSE and TASE : TEVA ) today reported results for the quarter ended September 30 , 2021 . Mr. Kåre Schultz , Teva's President and CEO , said , " I am very happy with our solid performance in the third quarter of 2021 , especially our strong cash flow and continued momentum with key brands . Our results were driven by robust performance of AJOVY® in the U.S. , Europe and Japan as well as U.S. sales of AUSTEDOⓇ , our novel therapy for the treatment of patients with Huntington's disease and tardive dyskinesia . We are also very enthusiastic about expanding our pipeline with additional movement disorder products in clinical development for multiple system atrophy ( MSA ) and Parkinson's disease , through the strategic collaboration announced yesterday with MODAG GmbH . " Mr. Schultz continued , " We are also proud to be launching a Sustainability - Linked Bond ( SLB ) today , which further demonstrates our commitment to the environment and to securing access to medicines in low and middle - income countries , two of the greatest challenges of our time . Teva is the first generics company to issue an SLB , furthering our leadership in accessible medicines for patients throughout the world . " IR Contacts PR Contacts Kevin C. Mannix Yael Ashman Kelley Dougherty Yonatan Beker ( 215 ) 591-8912 +972 ( 3 ) 914 8262 ( 973 ) 832-2810 ( 973 ) 917-0851